Merck&Co. Inc. has apparently backed away from a sale of its animal health unit after shedding its over-the-counter business for more than $14 billion dollars. Funds from that deal will provide ample cash to back acquisitions that will support growth of its veterinary medicine business. As global demand for meat rises and more people have the disposable income to own pets, deal activity in the space has climbed. Phibro Animal Health, for instance, went public about a month ago.